Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs
SourceClinical Infectious Diseases, 67, 11, (2018), pp. 1743-1749
Article / Letter to editor
Display more detailsDisplay less details
Clinical Infectious Diseases
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.